Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146588 · ClinicalTrials.gov registry record · NA
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
A NA study of Breast Cancer and Stage II Breast Cancer, sponsored by Craig A. Bunnell, MD, MPH.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT00146588 is a NA study of Breast Cancer and Stage II Breast Cancer that has completed, run by Craig A. Bunnell, MD, MPH. The registered enrollment target is 55 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00146588, a NA study of Breast Cancer and Stage II Breast Cancer, has completed, sponsored by Craig A. Bunnell, MD, MPH.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Capecitabine
- DRUG Epirubicin
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2002-04 |
| Est. Completion | 2004-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146588
The ClinicalTrials.gov registry entry for NCT00146588 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Craig A. Bunnell, MD, MPH, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00146588 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00146588 about?
NCT00146588 is a clinical study titled "Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer". The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
What is the current status of trial NCT00146588?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2002-04. Estimated completion is 2004-12.
What conditions does trial NCT00146588 study?
This clinical trial studies the following conditions: Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage I Breast Cancer.
What interventions are being tested in trial NCT00146588?
The interventions under investigation include: Cyclophosphamide (DRUG), Capecitabine (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT00146588?
This trial is sponsored by Craig A. Bunnell, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00146588 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.